BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37740714)

  • 1. Association of MRI leptomeningeal enhancement with disability worsening in progressive multiple sclerosis: A clinical and post-mortem study.
    Vercellino M; Costantini G; Cogoni M; Lequio L; Sciortino P; De Negri F; Marasciulo S; Valentini C; Bosa C; Garelli P; Rolando A; Calvo A; Morana G; Cavalla P
    Mult Scler; 2023 Nov; 29(13):1526-1539. PubMed ID: 37740714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leptomeningeal Enhancement on 3D-FLAIR MRI in Multiple Sclerosis: Systematic Observations in Clinical Practice.
    Titelbaum DS; Engisch R; Schwartz ED; Napoli SQ; Sloane JA; Samaan S; Katz JD; Lathi ES
    J Neuroimaging; 2020 Nov; 30(6):917-929. PubMed ID: 32830899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement.
    Bhargava P; Wicken C; Smith MD; Strowd RE; Cortese I; Reich DS; Calabresi PA; Mowry EM
    Mult Scler Relat Disord; 2019 May; 30():136-140. PubMed ID: 30771580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly Sensitive 3-Tesla Real Inversion Recovery MRI Detects Leptomeningeal Contrast Enhancement in Chronic Active Multiple Sclerosis.
    Okar SV; Dieckhaus H; Beck ES; Gaitán MI; Norato G; Pham DL; Absinta M; Cortese IC; Fletcher A; Jacobson S; Nair G; Reich DS
    Invest Radiol; 2024 Mar; 59(3):243-251. PubMed ID: 37493285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leptomeningeal enhancement in multiple sclerosis and other neurological diseases: A systematic review and Meta-Analysis.
    Ineichen BV; Tsagkas C; Absinta M; Reich DS
    Neuroimage Clin; 2022; 33():102939. PubMed ID: 35026625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis.
    Ighani M; Jonas S; Izbudak I; Choi S; Lema-Dopico A; Hua J; O'Connor EE; Harrison DM
    Mult Scler; 2020 Feb; 26(2):165-176. PubMed ID: 31573837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meningeal contrast enhancement in multiple sclerosis: Assessment of field strength, acquisition delay, and clinical relevance.
    Harrison DM; Allette YM; Zeng Y; Cohen A; Dahal S; Choi S; Zhuo J; Hua J
    PLoS One; 2024; 19(5):e0300298. PubMed ID: 38809920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot trial of ocrelizumab for modulation of meningeal enhancement in multiple sclerosis.
    Dahal S; Allette YM; Naunton K; Harrison DM
    Mult Scler Relat Disord; 2024 Jan; 81():105344. PubMed ID: 38035495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions.
    Zurawski J; Tauhid S; Chu R; Khalid F; Healy BC; Weiner HL; Bakshi R
    Mult Scler; 2020 Feb; 26(2):177-187. PubMed ID: 31714181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glial cell injury and atrophied lesion volume as measures of chronic multiple sclerosis inflammation.
    Jakimovski D; Qureshi F; Ramanathan M; Jalaleddini K; Ghoreyshi A; Dwyer MG; Bergsland N; Weinstock-Guttman B; Zivadinov R
    J Neurol Sci; 2024 Jun; 461():123055. PubMed ID: 38761669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focal cortical atrophy following transient meningeal enhancement in a progressive multiple sclerosis.
    Bonnan M; Money P; Desblache P; Marasescu R; Puvilland LM; Demasles S; Dahan C; Krim E; Tucholka A; Doyle S; Barroso B
    Neurol Sci; 2021 May; 42(5):1959-1961. PubMed ID: 32995987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of retinal atrophy with cortical lesions and leptomeningeal enhancement in multiple sclerosis on 7T MRI.
    Mizell R; Chen H; Lambe J; Saidha S; Harrison DM
    Mult Scler; 2022 Mar; 28(3):393-405. PubMed ID: 34125629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spinal cord lesions and brain grey matter atrophy independently predict clinical worsening in definite multiple sclerosis: a 5-year, multicentre study.
    Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Barkhof F; Schoonheim MM; Strijbis EM; Vrenken H; Gallo A; Bisecco A; Ciccarelli O; Yiannakas M; Rovira A; Sastre-Garriga J; Palace J; Matthews L; Gass A; Eisele P; Lukas C; Bellenberg B; Margoni M; Preziosa P; Filippi M;
    J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):10-18. PubMed ID: 36171105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leptomeningeal enhancement under different MS immunotherapies: A monocentric retrospective cohort study of 214 patients.
    Friedli C; Wagner F; Hammer HN; Kamber N; Wiest R; Diem L; Chan A; Salmen A; Hoepner R
    Mult Scler; 2023 Jan; 29(1):63-73. PubMed ID: 36113094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of volumetric MRI measures and disability in MS patients of the same age: Descriptions from a birth year cohort.
    de Ruiter LRJ; Loonstra FC; Jelgerhuis JR; Coerver EME; Toorop AA; van Leeuwen ICE; Noteboom S; Moraal B; Strijbis EMM; Schoonheim MM; Uitdehaag BMJ
    Mult Scler Relat Disord; 2023 Mar; 71():104568. PubMed ID: 36805177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningeal contrast enhancement in multiple sclerosis: assessment of field strength, acquisition delay, and clinical relevance.
    Harrison DM; Allette YM; Zeng Y; Cohen A; Dahal S; Choi S; Zhuo J; Hua J
    medRxiv; 2024 Mar; ():. PubMed ID: 38496664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases.
    Absinta M; Cortese IC; Vuolo L; Nair G; de Alwis MP; Ohayon J; Meani A; Martinelli V; Scotti R; Falini A; Smith BR; Nath A; Jacobson S; Filippi M; Reich DS
    Neurology; 2017 Apr; 88(15):1439-1444. PubMed ID: 28283598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation.
    Marchi L; Mariottini A; Viti V; Bianchi A; Nozzoli C; Repice AM; Boncompagni R; Ginestroni A; Damato V; Barilaro A; Chiti S; Saccardi R; Fainardi E; Massacesi L
    Front Neurol; 2024; 15():1373385. PubMed ID: 38899059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.
    Xiang B; Brier MR; Kanthamneni M; Wen J; Snyder AZ; Yablonskiy DA; Cross AH
    Mult Scler; 2022 Sep; 28(10):1515-1525. PubMed ID: 35196933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.
    Fisniku LK; Brex PA; Altmann DR; Miszkiel KA; Benton CE; Lanyon R; Thompson AJ; Miller DH
    Brain; 2008 Mar; 131(Pt 3):808-17. PubMed ID: 18234696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.